[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (16,041)

Search Parameters:
Keywords = implants

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
27 pages, 6354 KiB  
Review
Advances in the Study of Age-Related Macular Degeneration Based on Cell or Cell-Biomaterial Scaffolds
by Ziming Li, Zhiyong Hu and Zhixian Gao
Bioengineering 2025, 12(3), 278; https://doi.org/10.3390/bioengineering12030278 (registering DOI) - 11 Mar 2025
Abstract
Age-related macular degeneration (AMD), a progressive neurodegenerative disorder affecting the central retina, is pathologically defined by the irreversible degeneration of photoreceptors and retinal pigment epithelium (RPE), coupled with extracellular drusen deposition and choroidal neovascularization (CNV), and AMD constitutes the predominant etiological factor for [...] Read more.
Age-related macular degeneration (AMD), a progressive neurodegenerative disorder affecting the central retina, is pathologically defined by the irreversible degeneration of photoreceptors and retinal pigment epithelium (RPE), coupled with extracellular drusen deposition and choroidal neovascularization (CNV), and AMD constitutes the predominant etiological factor for irreversible vision impairment in adults aged ≥60 years. Cell-based or cell-biomaterial scaffold-based approaches have been popular in recent years as a major research direction for AMD; monotherapy with cell-based approaches typically involves subretinal injection of progenitor-derived or stem cell-derived RPE cells to restore retinal homeostasis. Meanwhile, cell-biomaterial scaffolds delivered to the lesion site by vector transplantation have been widely developed, and the implanted cell-biomaterial scaffolds can promote the reintegration of cells at the lesion site and solve the problems of translocation and discrete cellular structure produced by cell injection. While these therapeutic strategies demonstrate preliminary efficacy, rigorous preclinical validation and clinical trials remain imperative to validate their long-term safety, functional durability, and therapeutic consistency. This review synthesizes current advancements and translational challenges in cell-based and cell-biomaterial scaffold approaches for AMD, aiming to inform future development of targeted interventions for AMD pathogenesis and management. Full article
(This article belongs to the Section Biomedical Engineering and Biomaterials)
Show Figures

Figure 1

Figure 1
<p>Schematic representation of the progress of cell-based and cell-biomaterial scaffolds for AMD.</p>
Full article ">Figure 2
<p>Photomicrographs of 5 μm retinal sections, captured at 3 weeks post-treatment, demonstrate the survival of implanted cells (green) at the 3-week time point (<b>A</b>–<b>E</b>). The green fluorescence indicates the presence of photoreceptor precursor cells (pRPCs), while the blue fluorescence represents Hoechst counterstaining for nuclear visualization. Additionally, images taken 24 h post-implantation (<b>F</b>) are included for comparative analysis. Reprinted from Ref. [<a href="#B68-bioengineering-12-00278" class="html-bibr">68</a>].</p>
Full article ">Figure 3
<p>Subretinal engraftment of hESC-derived RPE cells in the albino rabbit model was evaluated through longitudinal multimodal imaging and histopathological analysis. (<b>A</b>) In vivo assessment utilizing multicolor confocal scanning laser ophthalmoscopy (cSLO) combined with spectral-domain optical coherence tomography (SD-OCT) demonstrated the structural integration of transplanted hESC-RPE cells at 1-, 4-, and 12-week postoperative intervals. The SD-OCT scan planes are demarcated by green reference lines. (<b>B</b>) Histological validation at the 4-week time point revealed successful RPE engraftment, as evidenced by bright-field microscopy and immunofluorescence staining for nuclear mitotic apparatus protein (NuMA) and bestrophin-1 (BEST-1), specific markers of RPE cellular integrity and functionality. Scale bars represent 200 μm for panel A and 50 μm for panel B. Reprinted from Ref. [<a href="#B77-bioengineering-12-00278" class="html-bibr">77</a>].</p>
Full article ">Figure 4
<p>RPE cell transplantation in RCS rats. (<b>A</b>,<b>B</b>) Fundus imaging (<b>A</b>) and hematoxylin and eosin (H&amp;E) staining (<b>B</b>) were performed on the eyes of RCS rats following subretinal injection of saline or retinal pigment epithelial (RPE) cells. The inset in (<b>A</b>) demonstrates the presence of human nuclear antigen-positive cells in the RPE-injected eye at postnatal day 90 (P90). (<b>C</b>) Assessment of visual function via optokinetic tracking revealed a significant improvement in visual acuity in RCS rats that received RPE transplantation compared to those injected with saline. (<b>D</b>) Immunohistochemical analysis of retinal sections using cone arrestin antibody was conducted to evaluate cone photoreceptor preservation following RPE transplantation. (<b>E</b>,<b>F</b>) Quantitative analysis of retinal thickness (<b>E</b>) and cone photoreceptor density (<b>F</b>) was performed in RCS rats receiving low and high doses of RPE transplantation. Measurements were taken from both the nasal and temporal regions of the retina. Scale bars represent 100 μm. Reprinted from Ref. [<a href="#B83-bioengineering-12-00278" class="html-bibr">83</a>].</p>
Full article ">Figure 5
<p>(<b>A</b>) Experimental design for the transplantation of induced retinal pigment epithelial (iRPE) cells in a sodium iodate (SI)-induced rat model of AMD. (<b>B</b>) ERG waveforms recorded at various time points post-transplantation. The calibration scale indicates 200 μV vertically and 25 ms horizontally. (<b>C</b>) Quantitative analysis of ERG b-wave amplitude (<span class="html-italic">n</span> = 10). Statistical significance was determined using one-way ANOVA followed by Bonferroni’s post hoc test. (<b>D</b>) Representative micrographs of retinal sections at 6 weeks post-transplantation. Injection sites are indicated by arrows, and the outer nuclear layer (ONL) is demarcated by yellow dashed lines. (<b>E</b>) Quantitative assessment of ONL thickness (μm) (<span class="html-italic">n</span> = 6). Statistical analysis was performed using one-way ANOVA with Bonferroni’s post hoc test. (<b>F</b>) Representative micrographs of retinal cryosections stained using the TUNEL assay to detect apoptotic cells. (<b>G</b>) Statistical analysis of the percentage of apoptotic cells within the ONL (<span class="html-italic">n</span> = 6). Data were analyzed using one-way ANOVA followed by Bonferroni’s post hoc test. (<b>H</b>) Immunostaining of human umbilical cord mesenchymal stem cells (hUCMSCs) and iRPE cells at 4 weeks post-transplantation in vivo. (<b>I</b>) Quantitative analysis of the percentage of immunostaining-positive grafted cells (<span class="html-italic">n</span> = 7). Statistical significance was determined using Student’s unpaired <span class="html-italic">t</span>-test. (<b>J</b>) Pigment epithelium-derived factor (PEDF) levels secreted by hUCMSCs and iRPE cells, as measured by ELISA (<span class="html-italic">n</span> = 4). Statistical analysis was performed using Student’s unpaired <span class="html-italic">t</span>-test. Scale bar = 50 μm. Data are presented as mean ± standard deviation (SD). Statistical significance is denoted as follows: ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 compared to the PBS control group; <sup>#</sup> <span class="html-italic">p</span> &lt; 0.05, <sup>##</sup> <span class="html-italic">p</span> &lt; 0.01 compared to the hUCMSC group; <sup><span>$</span></sup> <span class="html-italic">p</span> &lt; 0.05 compared to the PBS group. Adapted from Ref. [<a href="#B87-bioengineering-12-00278" class="html-bibr">87</a>].</p>
Full article ">
12 pages, 6685 KiB  
Article
Volume Restoration in Mid-Facial Aging: A Quantitative Evaluation of the Efficacy of Hyaluronic Acid Gel Injections—The Imperative to Optimize the Injection Volume Based on Anatomical Considerations
by Alberto Diaspro and Giuseppe Sito
Surgeries 2025, 6(1), 21; https://doi.org/10.3390/surgeries6010021 - 11 Mar 2025
Viewed by 60
Abstract
Background: The attractiveness of the central area (the so-called mid-face area or middle third) has a strong impact on the observer, and the treatment of aging in this area is therefore considered a key component in facial rejuvenation. A standardized photographic and three-dimensional [...] Read more.
Background: The attractiveness of the central area (the so-called mid-face area or middle third) has a strong impact on the observer, and the treatment of aging in this area is therefore considered a key component in facial rejuvenation. A standardized photographic and three-dimensional analysis was conducted in this observational study to determine the outcome of volumetric restoration procedures of the mid-face area with HA injection, providing an objective, repetitive, and reliable evaluation of this facial rejuvenation technique. Methods: In total, 47 patients were treated with two types of HA-based dermal fillers, and calibrated, stereoscopic images of the face were taken with volume reconstruction and analysis software performed before (t0), 45 days after HA implantation (t1), and at the check-up after the end of follow-up (t2). Results: In total, 39 out of 47 patients completed the study, which showed an overall volume restoration of 4.46 ± 1.34 mL at 45 days (t0–t1) after HA implantation, maintaining a value of 1.23 ± 0.68 mL at the end of the 318-day follow-up (t0–t2). Conclusions: The results of this study indicate that rejuvenation of the mid-facial region through volumetric restoration with an HA filler leads to an indirect volumetric effect that is clinically more significant than the actual injected volume and equally long-lasting. Full article
Show Figures

Figure 1

Figure 1
<p>Reference points: pre-tragal (point Ar—Articularis), lateral canthus (point Ex—Exocanthon), alar cartilage (point Al—Alare), and oral commissure (point Ch—Cheilon).</p>
Full article ">Figure 2
<p>Frontal view with color scale, after and before injection therapy—patient 1.</p>
Full article ">Figure 3
<p>Oblique view with color scale, after and before injection therapy—patient 1.</p>
Full article ">Figure 4
<p>Profile with color scale, after and before injection therapy—patient 1.</p>
Full article ">Figure 5
<p>Frontal view with color scale, after and before injection therapy—patient 2.</p>
Full article ">Figure 6
<p>Oblique view with color scale, after and before injection therapy—patient 2.</p>
Full article ">Figure 7
<p>Profile with color scale, after and before injection therapy—patient 2.</p>
Full article ">Figure 8
<p>Frontal view before and after injection therapy—patient 1.</p>
Full article ">Figure 9
<p>Oblique view before and after injection therapy—patient 1.</p>
Full article ">Figure 10
<p>Profile before and after injection therapy—patient 1.</p>
Full article ">Figure 11
<p>Frontal view before and after injection therapy—patient 2.</p>
Full article ">Figure 12
<p>Oblique view before and after injection therapy—patient 2.</p>
Full article ">Figure 13
<p>Profile before and after injection therapy—patient 2.</p>
Full article ">
15 pages, 7308 KiB  
Article
Novel Ti6Al4V Surface Treatment for Subperiosteal Dental Implants: Evaluation of Osteoblast-like Cell Proliferation and Osteogenic Response
by Roberto Campagna, Valentina Schiavoni, Loredana Rao, Fabrizio Bambini, Andrea Frontini, Francesco Sampalmieri, Eleonora Salvolini and Lucia Memé
Materials 2025, 18(6), 1234; https://doi.org/10.3390/ma18061234 - 11 Mar 2025
Viewed by 90
Abstract
Nowadays, custom-made subperiosteal implants are emerging as a solution in all those cases where there is lack of healthy bone tissue to support endosseous implants. The development of innovative techniques has allowed the production of grids that precisely match the patient’s anatomy. Elucidating [...] Read more.
Nowadays, custom-made subperiosteal implants are emerging as a solution in all those cases where there is lack of healthy bone tissue to support endosseous implants. The development of innovative techniques has allowed the production of grids that precisely match the patient’s anatomy. Elucidating the impact of laser-melted Ti6Al4V grids on both hard and soft tissues with which they come into contact is, therefore, mandatory. In this study, we analyzed the effects of five different surface treatments on a human osteoblast-like cell line (MG-63). In particular, the cell proliferation and osteogenic response were evaluated. Taken together, our data demonstrate that in our in vitro setting, the new surface treatment developed by Al Ti color could enhance osteogenesis and improve the stabilization of the implant to the residual bone by stimulating the best osteogenic response in MG-63 cells. Although further studies are required to validate our data in an in vivo model, our results provide the basis for future advances in implantology for the long-term maintenance of osseointegration. Full article
(This article belongs to the Special Issue Biomaterials for Bone Tissue Engineering (Second Edition))
Show Figures

Figure 1

Figure 1
<p>Low- and high-magnification (insets) SEM images of discs subject to different surface treatments. (<b>A</b>) CTRL disc; (<b>B</b>) EE disc; (<b>C</b>) ES disc. 3; (<b>D</b>) ATcs disc; (<b>E</b>) CA disc.</p>
Full article ">Figure 2
<p>The cell proliferation of MG-63 cells evaluated via MTT assay at different timepoints (0, 24, 48, and 72 h). Values are expressed as mean ± standard deviation; * <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">Figure 3
<p>Ki-67 expression levels evaluated by Real-Time PCR at 72 h. Values are expressed as mean ± standard deviation; * <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">Figure 4
<p>Representative confocal microscopy images of viable MG-63 cells cultured for 72 h on (<b>A</b>) control disc, (<b>B</b>) EE disc, (<b>C</b>) ES disc, (<b>D</b>) ATcs disc, and (<b>E</b>) CA disc. ProLong Glass Antifade Mountant with NucBlue was used for nuclei staining, while phalloidin was used to stain actin filaments. High-magnification pictures (20 µm scale bar) and inset with lower magnification pictures (50 µm scale bar).</p>
Full article ">Figure 5
<p>Heatmap of osteogenesis gene expression. Differential expression, at 72 h, of 84 genes involved in osteogenesis in MG-63 cells cultured on EE, ES, ATcs and CA discs compared to the control.</p>
Full article ">Figure 6
<p>Fold regulation of the indicated genes after 72 h of cell culture on ES and ATcs discs 4 compared to the control.</p>
Full article ">
15 pages, 5159 KiB  
Article
Cytocompatibility Study of Stainless Steel 316l Against Differentiated SH-SY5Y Cells
by Eleni Zingkou, Asimina Kolianou, Georgios Angelis, Michail Lykouras, Malvina Orkoula, Georgios Pampalakis and Georgia Sotiropoulou
Biomimetics 2025, 10(3), 169; https://doi.org/10.3390/biomimetics10030169 - 11 Mar 2025
Viewed by 96
Abstract
Stainless steel (SS) 316l constitutes a popular biomaterial with various applications as implants in cardiovascular and orthopedic surgery, as well as in dentistry. Nevertheless, its cytocompatibility against neuronal cells has not been investigated, a feature that is important for the construction of implants [...] Read more.
Stainless steel (SS) 316l constitutes a popular biomaterial with various applications as implants in cardiovascular and orthopedic surgery, as well as in dentistry. Nevertheless, its cytocompatibility against neuronal cells has not been investigated, a feature that is important for the construction of implants that require contact with neurons, e.g., neuronal electrodes. In addition, most cytocompatibility studies have focused on decorated or surface-modified SS 316l. On the other hand, SH-SY5Y cells are an established cellular model for cytocompatibility studies of potential biomaterials given their ability to differentiate into neuron-like cells. Here, we used retinoic-acid-differentiated SH-SY5Y cells and SH-SY5Y controls to investigate the cytocompatibility and biomimetics of uncoated SS 316l. The assessment of cytocompatibility was based on the determination of differentiation markers by immunofluorescence, RT-qPCR, and the neurite growth of these cells attached on SS 316l and standard tissue culture polystyrene (TCP) surfaces. Even though the neurite length was shorter in differentiated SH-SY5Y cells grown on SS 316l, no other significant changes were found. In conclusion, our results suggest that the uncoated SS 316l mimics a natural bio-surface and allows the adhesion, growth, and differentiation of SH-SY5Y cells. Therefore, this alloy can be directly applied in the emerging field of biomimetics, especially for the development of implants or devices that contact neurons. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Surface characterization of SS 316l before (<b>A</b>) and after immersion in PBS for 31 days (<b>B</b>). It is easily observed that no alteration of SS 316l composition or structure occurred during this period, indicating that this material is indeed resistant in solutions containing ions found in physiological fluids (mainly Cl<sup>−</sup>).</p>
Full article ">Figure 2
<p>Contact angle measurement. <b>Left</b>: actual image of water drop on the surface. <b>Right</b>: processed image and analysis with Ossila’s software (version 4.2.1). Blue color indicates the contact angle measurement on the left and dark red on the right side of the droplet.</p>
Full article ">Figure 3
<p>Morphological appearance of SH-SY5Y cells undifferentiated (<b>A</b>) and differentiated on TCP (<b>B</b>) and SS 316l (<b>C</b>,<b>D</b>). Undifferentiated SH-SY5Y cells appear small and oblong without long axial projections while differentiated SH-SY5Y cells appear more “neuron-like” and create a neurite network.</p>
Full article ">Figure 4
<p>Total cell number (<b>A</b>) and protein content (<b>B</b>) of SH-SY5Y cells deposited and differentiated on control material (TCP) or SS 316l. Values are shown as ±SD. No statistically significant difference was found (<span class="html-italic">p</span> &gt; 0.05).</p>
Full article ">Figure 5
<p>RT-qPCR analysis of <span class="html-italic">MAP2</span> and <span class="html-italic">NEFH</span> expression. The values are shown as ±SD.</p>
Full article ">Figure 6
<p>Analysis of MAP2 expression and the structure of the actin cytoskeleton with immunofluorescence. Nuclei were stained blue with DAPI. Merge indicates the merging of DAPI with MAP2. Actin was stained with phalloidin. The images were captured at 10× magnification with a fluorescence microscope. Scale bar: 100 μm.</p>
Full article ">Figure 7
<p>Distribution curves (<b>A</b>) and quantification of the mean axonal length (<b>B</b>) of differentiated SH-SY5Y cells grown on the TCP and SS 316l surfaces for 7 days and 14 days. The data are presented as ± SEM. The axon length value difference among SS 316l and the corresponding TCP control measured on days 7 and 14 is statistically significant (***: <span class="html-italic">p</span> &lt; 0.0001).</p>
Full article ">Figure 8
<p>Surface analysis of uncoated and coated SS 316l with RAMAN microscopy. (<b>A</b>) RAMAN spectra from the surface of uncoated SS 316l and SS 316l coated with collagen I. The experiment was carried out in duplicate (Experiment 1 and 2). (<b>B</b>) The yellow region in (<b>A</b>) is magnified to show the amide I region (1600–1700 cm<sup>−1</sup>). SS 316l does not show any peak in this region that may interfere with the amide I. Therefore, it is easily concluded that collagen has decorated the SS 316l surface.</p>
Full article ">Figure 9
<p>Assessment of in vitro cytotoxicity of SS 316l extract on differentiated SH-SY5Y cells. (<b>A</b>) Representative microphotographs of differentiated SH-SY5Y cells incubated with the SS 316l extract for 24 h after the application of MTT. The formazan crystals have stained the cells. (<b>B</b>) Staining of SH-SY5Y cells with neutral red (NR). Quantification of cellular viability with MTT (<b>C</b>) and neutral red (<b>D</b>). Data are expressed as % viability of differentiated cells and are presented as median ± SD from two independent experiments. All reactions were set up in triplicate in each experiment and 1% SDS was applied as a control since it lysed the cells. ns: not significant.</p>
Full article ">
12 pages, 1026 KiB  
Article
Efficacy and Safety of Percutaneous ASD Closure in Adults: Comparative Outcomes of Occluder Devices in a Single-Center Cohort
by Elham Kayvanpour, Elena Matzeit, Christoph Reich, Ziya Kaya, Sven Pleger, Norbert Frey, Benjamin Meder and Farbod Sedaghat-Hamedani
J. Clin. Med. 2025, 14(6), 1867; https://doi.org/10.3390/jcm14061867 - 10 Mar 2025
Viewed by 170
Abstract
Background: Atrial septal defect (ASD) is a prevalent congenital heart condition, resulting in left-to-right shunting. Untreated ASDs may be associated with complications, including right-sided heart failure, pulmonary hypertension, and atrial arrhythmias. Percutaneous ASD closure, performed with various occluder devices, has become the preferred [...] Read more.
Background: Atrial septal defect (ASD) is a prevalent congenital heart condition, resulting in left-to-right shunting. Untreated ASDs may be associated with complications, including right-sided heart failure, pulmonary hypertension, and atrial arrhythmias. Percutaneous ASD closure, performed with various occluder devices, has become the preferred approach for symptomatic patients with suitable anatomy, yet data on device-specific efficacy and safety profiles remain limited. Methods: This study was a retrospective, single-center analysis involving patients who underwent percutaneous ASD closure between January 2000 and February 2023. Data on patient characteristics, indications for the procedure, procedural details, and clinical outcomes were extracted from electronic medical records. Endpoints included complications at the puncture site, pericardial effusion, atrial arrhythmias, device-related thrombus formation, and overall survival. Results: A total of 195 patients were included (mean age 53.6 ± 16.2 years; 60.5% female). Three different devices were used: Amplatzer ASD occluder (n = 111), Gore Septal Occluder (n = 67), and Occlutech ASD occluder (n = 17). Initial procedural success rate was 90.8%, with no significant differences observed between devices. Periprocedural complication rates were low and comparable across all devices. New-onset atrial fibrillation within the first month post-implantation occurred in 7.5% of patients with the Gore device, compared to 0.9% with the Amplatzer device (p = 0.03) and 0% with the Occlutech device. No statistically significant differences were observed among the devices regarding thrombus formation, late-onset pericardial effusion, device erosion, or stroke. Conclusions: Percutaneous ASD closure demonstrates high procedural success and low complication rates across different occluder devices, supporting its efficacy and safety as a treatment for adults. Although the Gore device showed a higher incidence of new-onset AF compared to the Amplatzer device, no significant differences were observed regarding thrombus formation, pericardial effusion, device erosion or stroke. Full article
(This article belongs to the Special Issue Adult Congenital Heart Disease: Latest Advances and Prospects)
Show Figures

Figure 1

Figure 1
<p>Summary of the study comparing percutaneous ASD closure outcomes across different occluder devices. The graphical abstract highlights the study population, procedural success, residual shunt rates, and device-related complications, emphasizing the need for individualized device selection.</p>
Full article ">Figure 2
<p>Changes in NYHA classification between baseline and one month after ASD occlusion.</p>
Full article ">Figure 3
<p>Changes in systolic pulmonary artery pressure (PaSys) values across four time points, categorized by ASD occluder device.</p>
Full article ">
18 pages, 5955 KiB  
Article
Mathematical Modeling and Biomechanical Analysis of a Derotation Plate for Treating Complex Hip Dysplasia
by Durdana Oktyabrova, Kairat Ashimov, Berk Guclu, Mukhtar Abilmazhinov, Boris Gorbunov, Ramazanov Zhanatay, Timur Baidalin, Bekzhan Suleimenov, Askar Beknazarov, Bagdat Azamatov and Nail Beisekenov
Appl. Sci. 2025, 15(6), 2991; https://doi.org/10.3390/app15062991 - 10 Mar 2025
Viewed by 130
Abstract
Developmental dysplasia of the hip, particularly Crowe type IV, presents significant challenges in orthopedic surgery due to severe anatomical deformities and biomechanical instability. This study focuses on evaluating the biomechanical performance of a prosthesis–femur–derotation plate system designed to address these challenges. Using FEA, [...] Read more.
Developmental dysplasia of the hip, particularly Crowe type IV, presents significant challenges in orthopedic surgery due to severe anatomical deformities and biomechanical instability. This study focuses on evaluating the biomechanical performance of a prosthesis–femur–derotation plate system designed to address these challenges. Using FEA, a comprehensive assessment of stress distribution, displacement, and safety factors was conducted under physiological loading conditions. The derotation plate was specifically engineered to stabilize the femur and restore the anatomical and biomechanical axis of the limb. Results demonstrated that the derotation plate effectively eliminated rotational and axial displacement, with a peak displacement of 0.08 mm, and maintained sufficient strength reserves, with a minimum safety factor of 3.63. The maximum von Mises stress in the plate was 76 MPa, significantly below the yield strength of the titanium alloy, ensuring long-term durability and reliability. The system as a whole exhibited favorable biomechanical properties, confirming its ability to manage high stress loads without the risk of material failure or instability. These findings underscore the potential of this novel system to improve surgical outcomes in complex cases of hip dysplasia. Future clinical trials will further validate its practical utility, providing valuable insights for advancing orthopedic implant design and patient care. Full article
Show Figures

Figure 1

Figure 1
<p>Computer model of the studied “endoprosthesis–femur–derotation plate” system: (<b>a</b>) system view with anatomical context (femur, screws, plate, spokes), (<b>b</b>) system view with an emphasis on the structural fixation elements (derotation plate, screws, spokes).</p>
Full article ">Figure 2
<p>Finite element mesh of the system.</p>
Full article ">Figure 3
<p>Von Mises stress distribution (MPa): (<b>a</b>) stress on the femur under physiological loading, with maximum stress at the femoral head, (<b>b</b>) stress at the prosthesis–bone interface, showing concentrations in the prosthetic head region, (<b>c</b>) stress on the derotation plate, with maximum stress near the screw holes.</p>
Full article ">Figure 4
<p>Displacement of system elements (mm): (<b>a</b>) displacement of the femur under applied physiological loading, with maximum values observed at the prosthetic head, (<b>b</b>) displacement distribution at the prosthesis–bone interface, showing the highest displacement at the prosthetic head region, (<b>c</b>) displacement of the derotation plate, with minimal values concentrated near the plate body and screws, indicating its stabilizing role. The arrows in the figure represent the applied loading directions in the finite element analysis.</p>
Full article ">Figure 5
<p>Safety factor of the system: (<b>a</b>) safety factor distribution for the femur under applied loading, with the minimum value of 1.24 observed near the cortical bone, (<b>b</b>) safety factor at the prosthesis–bone interface, showing a minimum value of 2.26 near the prosthetic neck region, (<b>c</b>) safety factor of the derotation plate, with a minimum value of 3.63 localized near the screw holes, indicating sufficient strength reserves. The arrows in the figure represent the applied loading directions in the finite element analysis.</p>
Full article ">Figure 6
<p>von Mises stress on the derotation plate, ranging from 0 to 20 MPa.</p>
Full article ">Figure 7
<p>Radiograph of the hip joints of a patient with Crowe type IV dysplasia of the left hip joint: (<b>a</b>) before surgery, (<b>b</b>) three months after surgery.</p>
Full article ">Figure A1
<p>Preparation of the true acetabulum during total hip arthroplasty, illustrating the precise location and use of reamers to prepare the acetabular cavity.</p>
Full article ">Figure A2
<p>Osteosynthesis of the subtrochanteric transverse shortening osteotomy using a custom-designed derotation plate with locking screws for stabilization.</p>
Full article ">Figure A3
<p>Osteotomized femoral fragment.</p>
Full article ">
31 pages, 2070 KiB  
Review
Advances in Magnesium-Based Biomaterials: Strategies for Enhanced Corrosion Resistance, Mechanical Performance, and Biocompatibility
by Yushun Liu, Jian Yin and Guo-zhen Zhu
Crystals 2025, 15(3), 256; https://doi.org/10.3390/cryst15030256 - 10 Mar 2025
Viewed by 154
Abstract
Magnesium (Mg) and its alloys have emerged as promising biomaterials for orthopedic and cardiovascular applications, thanks to their good biodegradability, biocompatibility, and mechanical properties close to that of natural bone. However, the rapid degradation of Mg in physiological environments and limited mechanical performance [...] Read more.
Magnesium (Mg) and its alloys have emerged as promising biomaterials for orthopedic and cardiovascular applications, thanks to their good biodegradability, biocompatibility, and mechanical properties close to that of natural bone. However, the rapid degradation of Mg in physiological environments and limited mechanical performance tend to compromise the structural integrity of implants before healing is complete. These drawbacks have been heavily limiting the application of Mg and its alloys as biomaterials. In this paper, we review recent advancements in two common solutions to these problems: alloying and surface treatment, with a focus on controlling the corrosion resistance, mechanical performance, and biocompatibility of Mg-based biomaterials. Full article
(This article belongs to the Special Issue Development of Light Alloys and Their Applications)
Show Figures

Figure 1

Figure 1
<p>(<b>a</b>) Stiffness evolution with time for ideal biodegradable materials; (<b>b</b>) illustration of the degradation process of the Mg implant inside the human body [<a href="#B20-crystals-15-00256" class="html-bibr">20</a>]. The presence of Mg ions introduced by scaffolds promotes the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Enhanced osteogenesis has also been observed due to increased angiogenesis, including a higher percentage of CD31<sup>hi</sup> Endomucin<sup>hi</sup> (CD31<sup>hi</sup>Emcn<sup>hi</sup>) endothelial cells (ECs). Moreover, the scaffolds can produce the neuropeptide calcitonin gene-related peptide (CGRP) by triggering trigeminal neurons, leading to further improved angiogenesis and osteogenesis.</p>
Full article ">Figure 2
<p>Major deformation modes at room temperature for Mg alloys [<a href="#B21-crystals-15-00256" class="html-bibr">21</a>].</p>
Full article ">Figure 3
<p>Schematic illustration of (<b>a</b>) ECAP [<a href="#B132-crystals-15-00256" class="html-bibr">132</a>] and (<b>b</b>) HPT [<a href="#B133-crystals-15-00256" class="html-bibr">133</a>].</p>
Full article ">Figure 4
<p>Comparison of the corrosion rate and flow stress of Mg alloys subjected to ECAP and HPT from Ref. [<a href="#B139-crystals-15-00256" class="html-bibr">139</a>].</p>
Full article ">Figure 5
<p>Schematic diagram showing the principles of different SSPDs: (<b>a</b>) UNSM, (<b>b</b>) SMAT, and (<b>c</b>) SP.</p>
Full article ">
15 pages, 1798 KiB  
Article
Radiological Insights into Acellular Dermal Matrix Integration in Post-Mastectomy Breast Reconstruction: Implications for Cancer Patient Management
by Luciano Mariano, Andrea Lisa, Luca Nicosia, Anna Carla Bozzini, Sergio Miranda, Manuela Bottoni, Valeria Zingarello, Filippo Pesapane, Mario Rietjens and Enrico Cassano
Cancers 2025, 17(6), 933; https://doi.org/10.3390/cancers17060933 - 10 Mar 2025
Viewed by 133
Abstract
Background: Breast reconstruction (BR) following mastectomy plays a critical role in restoring breast contour and improving patients’ quality of life. Acellular dermal matrices (ADMs) have emerged as valuable adjuncts in BR, providing structural support and enhancing soft tissue integration. However, their radiological characteristics [...] Read more.
Background: Breast reconstruction (BR) following mastectomy plays a critical role in restoring breast contour and improving patients’ quality of life. Acellular dermal matrices (ADMs) have emerged as valuable adjuncts in BR, providing structural support and enhancing soft tissue integration. However, their radiological characteristics remain underexplored, leading to potential misinterpretation and diagnostic challenges. This study aims to evaluate the imaging features of ADM in post-mastectomy patients using conventional imaging modalities, identifying its temporal evolution and clinical implications for radiologists and surgeons. Materials and Methods: This single-centre retrospective study included breast cancer patients who underwent mastectomy followed by ADM-assisted BR. Patients were monitored using standardised radiological follow-up protocols, including digital mammography (DM) and ultrasound (US), at 6 (T0), 12 (T1), and 18 months (T2) postoperatively. The primary outcomes assessed were the presence and evolution of ADM-related imaging findings, differentiation between normal ADM integration and pathological changes, and the role of different imaging modalities in ADM evaluation. Results: Sixty-three patients met the inclusion criteria and underwent radiological follow-up. At T0, ADM was identified in 16% of cases, primarily as a peri-capsular hypoechoic thickening on US and a linear peri-implant density on DM. At T1, these findings were partially resolved, with 11% of cases still displaying peri-capsular changes. By T2, imaging signs of ADM were further reduced, with only 7% of cases showing residual peri-capsular thickening or pseudonodular formations. No ADM-related complications, graft rejection, or implant loss were detected. These findings suggest a progressive integration of ADM into the host tissue over time, with characteristic imaging changes that must be recognised to avoid misdiagnosis or unnecessary interventions. Conclusions: ADM exhibits a dynamic radiological evolution in post-mastectomy BR, with its imaging characteristics gradually fading. Recognising these features is critical for radiologists and surgeons to ensure accurate interpretation and optimised patient management. A structured imaging follow-up protocol, incorporating US as the primary modality and MRI in cases of inconclusive findings, is recommended to improve diagnostic accuracy. Future multicentre studies with extended follow-up and advanced imaging techniques are necessary to refine radiological criteria and further explore ADM integration patterns. A multidisciplinary approach is essential to enhance clinical decision-making, reduce unnecessary interventions, and optimise patient outcomes in ADM-assisted BR. Full article
(This article belongs to the Special Issue Trends in Mastectomy and Breast Reconstruction for Cancer)
Show Figures

Figure 1

Figure 1
<p>Flowchart of the study.</p>
Full article ">Figure 2
<p>ADM features on US. ADM is observed as a peri-capsular hypoechoic thickening (red arrows) on the implant profile (<b>a</b>–<b>d</b>).</p>
Full article ">Figure 3
<p>ADM features on US. The US scans of patients undergoing nipple-sparing mastectomy show a homogeneous hypoechoic peri-implant thickening (red arrows) at 6 months (<b>a</b>), gradually reduced at 12 (<b>b</b>) and 18 (<b>c</b>) months by ADM integration in the soft tissues of the host.</p>
Full article ">Figure 4
<p>ADM features on US. A focal hypoechogenic lesion on the implant profile (red arrows) may be a normal finding post-BR with implant and ADM (<b>a</b>,<b>b</b>).</p>
Full article ">Figure 5
<p>ADM features on DM. The medio-lateral-oblique DM view (<b>a</b>) and the targeted magnification (<b>b</b>) of the left breast approximately six months after nipple-sparing mastectomy with implant reconstruction and placement of porcine-derived ADM show a linear thickening (red arrow) on the lower profile.</p>
Full article ">Figure 6
<p>ADM features on DM. The medio-lateral-oblique DM views of the right breast after nipple-sparing mastectomy with implant reconstruction and placement of porcine-derived ADM show a peri-implant linear thickening (red arrows) at six months (<b>a</b>), reduced at 12 months (<b>b</b>) and completely disappeared at 18 months (<b>c</b>).</p>
Full article ">
16 pages, 51289 KiB  
Article
Characterization and Modelling of Biomimetic Bone Through Additive Manufacturing
by Niranjan Srinivasan, Mohsen Barmouz and Bahman Azarhoushang
J. Manuf. Mater. Process. 2025, 9(3), 87; https://doi.org/10.3390/jmmp9030087 - 10 Mar 2025
Viewed by 81
Abstract
The long-term success of bone implant scaffolds depends on numerous factors, such as their porosity, mechanical properties, and biocompatibility. These properties depend on the type of material, such as metals and their alloys or ceramics, and the procedure used to create the scaffolds. [...] Read more.
The long-term success of bone implant scaffolds depends on numerous factors, such as their porosity, mechanical properties, and biocompatibility. These properties depend on the type of material, such as metals and their alloys or ceramics, and the procedure used to create the scaffolds. This study aims to find the biomimetic properties of aluminum 6061 (Al 6061) alloy through Digital Light Processing (DLP) and sintering. Hollow cylindrical Al 6061 samples are printed through the DLP process at 90, 110, and 130 Wt.% aluminum powder concentrations inside a photocurable resin. The ideal temperature at which the material is sintered is 550 °C for 130 and 110 Wt.% and 530 °C for 90 Wt.%. The overall pore size ranges in the Al 6061 of these three concentrations from 30 μm to 700 μm. The compression test revealed the materials’ Ultimate Tensile Strengths (UTSs) to be 1.72, 2.2, and 1.78 MPa for the 90, 110, and 130 Wt.% materials, respectively. A simulation of the Al 6061 material as linear isotropic resulted in the UTS being 2.2 MPa. This novel hybrid of the additive manufacturing method and sintering created a scaffold model with anisotropic properties closer to trabecular bone, which could be used to observe fracture progression and could be tested for implant capabilities. Full article
(This article belongs to the Special Issue Emerging Methods in Digital Manufacturing)
Show Figures

Figure 1

Figure 1
<p>A sintered Al 6061 foam sample.</p>
Full article ">Figure 2
<p>Sintering plot for single ramp.</p>
Full article ">Figure 3
<p>Sintered Al 6061 150% single ramp under (<b>A</b>) cycle 1, (<b>B</b>) cycle 2, (<b>C</b>) cycle 3, (<b>D</b>) cycle 4, and (<b>E</b>) cycle 5.</p>
Full article ">Figure 4
<p>Sintered Al 6061 75% single-ramp grains: (<b>A</b>) cycle 1, (<b>B</b>) cycle 2, (<b>C</b>) cycle 3, and (<b>D</b>) cycle 4.</p>
Full article ">Figure 5
<p>Sintering plot for double ramp.</p>
Full article ">Figure 6
<p>Sintered Al 6061 grains for 130% and 150% from double-ramp sintering: (<b>A</b>,<b>B</b>) 130% concentration for cycle 1, (<b>C</b>,<b>D</b>) 150% concentration for cycle 3, and (<b>E</b>) 150% concentration for cycle 4.</p>
Full article ">Figure 7
<p>Al 6061—90% concentration sample observed under the microscope.</p>
Full article ">Figure 8
<p>Al 6061—110% concentration sample observed under the microscope.</p>
Full article ">Figure 9
<p>Al 6061—130% concentration sample observed under the microscope.</p>
Full article ">Figure 10
<p>Al 6061—aluminum 6061 90% concentrated scaffold with open cell structure.</p>
Full article ">Figure 11
<p>Al 6061—aluminium 6061 110% concentrated scaffold with open cell structure.</p>
Full article ">Figure 12
<p>Test setup.</p>
Full article ">Figure 13
<p>Compression test result for Al 6061 130% samples.</p>
Full article ">Figure 14
<p>Compression test result for Al 6061 110% samples.</p>
Full article ">Figure 15
<p>Compression test result for Al 6061 90% samples.</p>
Full article ">Figure 16
<p>Stress state for an applied force of 30 N.</p>
Full article ">Figure 17
<p>Stress state for an applied force of 230 N.</p>
Full article ">Figure 18
<p>Al 6061 hollow cylinder under uniaxial compression test.</p>
Full article ">
12 pages, 1538 KiB  
Article
Properties of a Static Dipolar Impurity in a 2D Dipolar BEC
by Neelam Shukla and Jeremy R. Armstrong
Atoms 2025, 13(3), 24; https://doi.org/10.3390/atoms13030024 - 10 Mar 2025
Viewed by 128
Abstract
We study a system of ultra-cold dipolar Bose gas atoms confined in a two-dimensional (2D) harmonic trap with a dipolar impurity implanted at the center of the trap. Due to recent experimental progress in dipolar condensates, we focused on calculating properties of dipolar [...] Read more.
We study a system of ultra-cold dipolar Bose gas atoms confined in a two-dimensional (2D) harmonic trap with a dipolar impurity implanted at the center of the trap. Due to recent experimental progress in dipolar condensates, we focused on calculating properties of dipolar impurity systems that might guide experimentalists if they choose to study impurities in dipolar gases. We used the Gross–Pitaevskii formalism solved numerically via the split-step Crank–Nicolson method. We chose parameters of the background gas to be consistent with dysprosium (Dy), one of the strongest magnetic dipoles and of current experimental interest, and used chromium (Cr), erbium (Er), terbium (Tb), and Dy for the impurity. The dipole moments were aligned by an external field along what was chosen to be the z-axis, and we studied 2D confinements that were perpendicular or parallel to the external field. We show density contour plots for the two confinements, 1D cross-sections of the densities, calculated self-energies of the impurities while varying both number of atoms in the condensate and the symmetry of the trap. We also calculated the time evolution of the density of an initially pure system where an impurity is introduced. Our results show that while the self-energy increases in magnitude with increasing number of particles, it is reduced when the trap anisotropy follows the natural anisotropy of the gas, i.e., elongated along the z-axis in the case of parallel confinement. This work builds upon work conducted in Bose gases with zero-range interactions and demonstrates some of the features that could be found when exploring dipolar impurities in 2D Bose gases. Full article
(This article belongs to the Section Cold Atoms, Quantum Gases and Bose-Einstein Condensation)
Show Figures

Figure 1

Figure 1
<p>Shown in panel (<b>a</b>) is a density contour plot for a dipolar gas consisting of 2000 Dy atoms confined in the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>y</mi> </mrow> </semantics></math>-plane with dipole moments polarized perpendicular to the plane with an impurity Dy atom at the origin. Panel (<b>b</b>) shows a one-dimensional (1D) cross−section of the density taken along the <span class="html-italic">x</span>-axis for three different impurities as well as the cross−section of the system without an impurity. This inset in panel (<b>b</b>) shows a close-up of the profile near the origin. The <span class="html-italic">y</span>-axis cross-section is not shown, as the system is isotropic, and thus, it is identical to the <span class="html-italic">x</span>-axis cross-section.</p>
Full article ">Figure 2
<p>Self−energy, Equation (<a href="#FD1-atoms-13-00024" class="html-disp-formula">1</a>), of an impurity implanted into a dipolar gas confined to the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>y</mi> </mrow> </semantics></math>-plane as a function of the number of particles in the dipolar gas for four different impurities.</p>
Full article ">Figure 3
<p>Shown in panel (<b>a</b>) is a density contour plot for a dipolar gas consisting of 2000 Dy atoms confined in the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>z</mi> </mrow> </semantics></math>-plane with dipole moments polarized parallel to the plane with an impurity Dy atom at the origin. Panels (<b>b</b>,<b>c</b>) show one-dimensional density cross-sections along the <span class="html-italic">x</span>- and <span class="html-italic">z</span>-axes, respectively, for three different impurities and the no-impurity system. Panels (<b>b</b>,<b>c</b>) also show insets showing a close up of the density profiles near the origin.</p>
Full article ">Figure 4
<p>Self-energy, Equation (<a href="#FD1-atoms-13-00024" class="html-disp-formula">1</a>), of an impurity implanted into a dipolar gas confined to the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>z</mi> </mrow> </semantics></math>-plane as a function of the number of particles in the dipolar gas for four different impurities.</p>
Full article ">Figure 5
<p>Self-energy plotted as a function of the deformation <math display="inline"><semantics> <mi>ε</mi> </semantics></math> for four different impurities. These plots were obtained for a system of 2000 Dy atoms confined in the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>z</mi> </mrow> </semantics></math>-plane with their dipole moments aligned along the <span class="html-italic">z</span>-axis.</p>
Full article ">Figure 6
<p>(<b>a</b>,<b>b</b>) Density contour plots for a system of 2000 Dy atoms confined in the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>z</mi> </mrow> </semantics></math>-plane. Here, the confining harmonic trap has been deformed as described in Equation (<a href="#FD2-atoms-13-00024" class="html-disp-formula">2</a>), and these results are for the most extreme deformations we considered, which are <math display="inline"><semantics> <mrow> <mi>ε</mi> <mo>=</mo> <mo>±</mo> <mn>3.75</mn> </mrow> </semantics></math>.</p>
Full article ">Figure 7
<p>Density profiles along the <span class="html-italic">x</span>-axis (<b>a</b>) and the <span class="html-italic">z</span>-axis (<b>b</b>) for different amounts of time evolution. At <math display="inline"><semantics> <mrow> <mi>t</mi> <mo>=</mo> <mn>0</mn> </mrow> </semantics></math>, the dipolar BEC of 2000 Dy atoms confined in the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>z</mi> </mrow> </semantics></math> plane has a Dy impurity implanted at the origin. The time unit, <math display="inline"><semantics> <msup> <mi>ω</mi> <mrow> <mo>−</mo> <mn>1</mn> </mrow> </msup> </semantics></math>, corresponds to about 2.5 ms.</p>
Full article ">Figure 8
<p>Density profile along the <span class="html-italic">x</span>-axis for different amounts of time evolution. For the same gas as in <a href="#atoms-13-00024-f007" class="html-fig">Figure 7</a>, only this gas is confined to the <math display="inline"><semantics> <mrow> <mi>x</mi> <mi>y</mi> </mrow> </semantics></math> plane. Since the system is isotropic, the profile along the <span class="html-italic">y</span>-axis is identical.</p>
Full article ">
15 pages, 14523 KiB  
Article
Porcine Recombinant NK-Lysin Inhibits the Growth and Metastasis of Murine Hepatocellular Carcinoma In Vivo
by Kuohai Fan, Zhiwei Feng, Dahai Zhao, Xiaozhong Zheng, Wei Yin, Na Sun, Panpan Sun and Hongquan Li
Molecules 2025, 30(6), 1234; https://doi.org/10.3390/molecules30061234 - 10 Mar 2025
Viewed by 172
Abstract
Porcine recombinant NK-lysin (prNK-lysin) has been shown to inhibit the proliferation and metastasis of hepatocellular carcinoma (HCC) cells in vitro. However, its effects on the proliferation and metastasis of HCC cells in vivo remain unclear. In this study, an allograft murine model using [...] Read more.
Porcine recombinant NK-lysin (prNK-lysin) has been shown to inhibit the proliferation and metastasis of hepatocellular carcinoma (HCC) cells in vitro. However, its effects on the proliferation and metastasis of HCC cells in vivo remain unclear. In this study, an allograft murine model using the murine HCC cell line Hepa1-6 was employed to investigate the anticancer effects of prNK-lysin. Initially, the in vitro anticancer efficacy of prNK-lysin was evaluated in Hepa1-6 cells, demonstrating that prNK-lysin effectively inhibited both proliferation and metastasis. These effects were mediated through the induction of oncosis and suppression of Fascin-1, MMP-2, and MMP-9 protein expressions. Subsequently, the in vivo anticancer efficacy of prNK-lysin was assessed using a mouse liver orthotopic implantation model and a lung metastasis model of Hepa1-6 cells in BALB/cA-nu mice. The administration of 13 mg/kg of prNK-lysin could inhibit tumor growth in the liver and metastasis to the lungs. Our results demonstrate that prNK-lysin possesses strong anti-HCC effects both in vitro and in vivo, with the induction of oncosis and the inhibition of Fascin-1, MMP-2, and MMP-9 protein expressions as potential molecular mechanisms for its anticancer activity. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Inhibition rate of prNK-lysin on AML-12 hepatocytes and Hepa1-6 cells. (<b>a</b>) AML-12 hepatocytes were treated with the indicated concentration of prNK-lysin for 6 h, 12 h, 24 h, 48 h, and 72 h, (<b>b</b>) Hepa1-6 cells were treated with the indicated concentration of prNK-lysin for 6 h, 12 h, and 24 h.</p>
Full article ">Figure 2
<p>An Annexin V and PI double staining assay was used to analyze the effect of the treatment with prNK-lysin for 24 h. (<b>a</b>) Flow cytometry plots, (<b>b</b>) the bar statistics of the FITC<sup>+</sup>/PI<sup>−</sup> cells rate, (<b>c</b>) the bar statistics of the FITC<sup>+</sup>/PI<sup>+</sup> cells rate. The ns means not statistically significant, and **** indicates <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 3
<p>The expression of Caspase-3 in the Hepa1-6 cells treated with different concentrations of prNK-lysin for 24 h. (<b>a</b>) Images of Western blotting, (<b>b</b>) the bar statistics of expression of Caspase-3. Caspase-3 band intensities were quantified by Image J (v1.8.0) after GAPDH normalization. The ns means not statistically significant.</p>
Full article ">Figure 4
<p>The morphological changes in the Hepa1-6 cells treated with 12 μM of prNK-lysin for 6 h and 12 h were observed by Inverted Microscope (Scale bar = 10 μm. Yellow arrow →: membrane surface blebs, Red arrow →: cellular swelling).</p>
Full article ">Figure 5
<p>The morphological changes in the Hepa1-6 cells treated with 12 μM of prNK-lysin for 6 h and 12 h were observed by Transmission Electron Microscope (Scale bar = 1 μm and 0.2 μm. N: Nuclear, M: Mitochondria, R: Ribosome, L: Lysosome, B: Blebbing).</p>
Full article ">Figure 6
<p>Lactate dehydrogenase (LDH) release in Hepa1-6 cells treated with different concentrations of prNK-lysin for 6 h and 12 h. The ns means not statistically significant, and **** indicates <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 7
<p>The expression of Porimin in the Hepa1-6 cells treated with different concentrations of prNK-lysin for 24 h. (<b>a</b>) Images of Western blotting, (<b>b</b>) the bar statistics of expression of Porimin. Porimin band intensities were quantified by Image J (v1.8.0) after GAPDH normalization. The ns means not statistically significant, * indicates <span class="html-italic">p</span> &lt; 0.05, and **** indicates <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 8
<p>The scratch healing and adhesion of the Hepa1-6 cells treated with different concentrations of prNK-lysin for 24 h was observed and analyzed. (<b>a</b>) Images of scratch healing of the Hepa1-6 cells (scale = 50 μm), (<b>b</b>) the bar statistics of scratch healing of the Hepa1-6 cells, (<b>c</b>) the bar statistics of adhesion of the Hepa1-6 cells. The ns means not statistically significant, *** indicates <span class="html-italic">p</span> &lt; 0.001, and **** indicates <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 9
<p>The migration and invasion of the Hepa1-6 cells treated with different concentrations of prNK-lysin for 24 h was observed and analyzed. (<b>a</b>) Images of migration and invasion of the Hepa1-6 cells (scale = 200 μm), (<b>b</b>) the bar statistics of migration and invasion of the Hepa1-6 cells. The ns means not statistically significant, and **** indicates <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 10
<p>The expressions of Fascin-1, MMP-2, and MMP-3 in the Hepa1-6 cells treated with different concentrations of prNK-lysin for 24 h. (<b>a</b>) Images of Western blotting, (<b>b</b>–<b>d</b>) the bar statistics of expression of Fascin-1, MMP-2 and MMP-9. Fascin-1, MMP-2, and MMP-9 band intensities were quantified by Image J (v1.8.0) after GAPDH normalization. The ns means not statistically significant, ** indicates <span class="html-italic">p</span> &lt; 0.01, *** indicates <span class="html-italic">p</span> &lt; 0.001, and **** indicates <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 11
<p>Changes in body weight observed using mouse liver orthotopic implantation model.</p>
Full article ">Figure 12
<p>The growth of Hepa1-6 cells in mouse liver orthotopic implantation model. (<b>a</b>) Images of tumor and liver tissues observed under mouse liver orthotopic implantation model, (<b>b</b>) The bar statistics of liver index. The ns means not statistically significant, and * indicates <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">Figure 13
<p>Histology of tumor and liver tissue staining with HE (Scale bar = 200 μm, Yellow arrow →: Cancerous tissue).</p>
Full article ">Figure 14
<p>Changes in the body weight under the mouse lung metastasis model.</p>
Full article ">Figure 15
<p>The metastasis of Hepa1-6 cells in mouse lung metastasis model. (<b>a</b>) Images of lung tissues under the mouse lung metastasis model, (<b>b</b>) The bar statistics of number of lung tumor nodules. The ns means not statistically significant, and * indicates <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">Figure 16
<p>Histology of tumor and lung tissue staining with HE (Scale bar = 200 μm, Yellow arrow →: Cancerous tissue).</p>
Full article ">
17 pages, 963 KiB  
Systematic Review
Incidence, Pathogenesis, Risk Factors, and Treatment of Cystoid Macula Oedema Following Cataract Surgery: A Systematic Review
by Lorenzo Ferro Desideri, Kirupakaran Arun, Enrico Bernardi, Nicola Sagurski and Rodrigo Anguita
Diagnostics 2025, 15(6), 667; https://doi.org/10.3390/diagnostics15060667 (registering DOI) - 10 Mar 2025
Viewed by 147
Abstract
Background/Objectives: Cystoid macular edema (CMO) is a common complication that follows cataract surgery, presenting management challenges due to the lack of standardized treatment guidelines and the potential for spontaneous resolution. This study aimed to evaluate various treatment modalities for post-operative CMO, including topical [...] Read more.
Background/Objectives: Cystoid macular edema (CMO) is a common complication that follows cataract surgery, presenting management challenges due to the lack of standardized treatment guidelines and the potential for spontaneous resolution. This study aimed to evaluate various treatment modalities for post-operative CMO, including topical non-steroidal anti-inflammatory drugs (NSAIDs), periocular steroids, and intravitreal injections. Methods: A systematic review of the literature was conducted to assess the efficacy of different treatment approaches for post-operative CMO. Studies evaluating topical NSAIDs, periocular steroids, intravitreal triamcinolone acetonide (TCA), dexamethasone implants (Ozurdex), and intravitreal bevacizumab were included. The main outcomes assessed included improvements in vision, resolution of CMO, recurrence rates, and safety profile. Results: Topical NSAIDs, particularly ketorolac and diclofenac, showed effectiveness in acute CMO, while their efficacy in chronic cases was variable. Periocular steroids, including retrobulbar TCA and sub-Tenon injections, demonstrated significant improvements in vision and the resolution of CMO, especially in cases resistant to topical therapy. Intravitreal TCA and dexamethasone implants exhibited variable effects on CMO resolution and recurrence rates, with some studies reporting sustained improvements over 12 months. The role of intravitreal bevacizumab as initial therapy remains unclear, although it may be considered in cases unresponsive to steroids. Conclusions: Topical NSAIDs, often combined with periocular steroids, serve as first-line therapy, with periocular steroids offering additional efficacy in resistant cases. Further research is needed to establish optimal treatment algorithms and improve outcomes for patients with post-operative CMO Full article
(This article belongs to the Section Clinical Diagnosis and Prognosis)
Show Figures

Figure 1

Figure 1
<p><b>PRISMA 2020 flow diagram for new systematic reviews that included searches of databases and registers only.</b> * Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). ** If automation tools were used, indicate how many records were excluded by a human and how many were excluded by the automation tools.</p>
Full article ">Figure 2
<p>Optical coherence tomography image demonstrating localized foveal oedema and perifoveal cystic spaces that are seen in post-operative cystoid macula oedema. White bar 0.5 mm.</p>
Full article ">
21 pages, 2314 KiB  
Article
High Accuracy of Epileptic Seizure Detection Using Tiny Machine Learning Technology for Implantable Closed-Loop Neurostimulation Systems
by Evangelia Tsakanika, Vasileios Tsoukas, Athanasios Kakarountas and Vasileios Kokkinos
BioMedInformatics 2025, 5(1), 14; https://doi.org/10.3390/biomedinformatics5010014 - 10 Mar 2025
Viewed by 225
Abstract
Background: Epilepsy is one of the most common and devastating neurological disorders, manifesting with seizures and affecting approximately 1–2% of the world’s population. The criticality of seizure occurrence and associated risks, combined with the overwhelming need for more precise and innovative treatment methods, [...] Read more.
Background: Epilepsy is one of the most common and devastating neurological disorders, manifesting with seizures and affecting approximately 1–2% of the world’s population. The criticality of seizure occurrence and associated risks, combined with the overwhelming need for more precise and innovative treatment methods, has led to the development of invasive neurostimulation devices programmed to detect and apply electrical stimulation therapy to suppress seizures and reduce the seizure burden. Tiny Machine Learning (TinyML) is a rapidly growing branch of machine learning. One of its key characteristics is the ability to run machine learning algorithms without the need for high computational complexity and powerful hardware resources. The featured work utilizes TinyML technology to implement an algorithm that can be integrated into the microprocessor of an implantable closed-loop brain neurostimulation system to accurately detect seizures in real-time by analyzing intracranial EEG (iEEG) signals. Methods: A dataset containing iEEG signal values from both non-epileptic and epileptic individuals was utilized for the implementation of the proposed algorithm. Appropriate data preprocessing was performed, and two training datasets with 1000 records of non-epileptic and epileptic iEEG signals were created. A test dataset with an independent dataset of 500 records was also created. The web-based platform Edge Impulse was used for model generation and visualization, and different model architectures were explored and tested. Finally, metrics of accuracy, confusion matrices, and ROC curves were used to evaluate the performance of the model. Results: Our model demonstrated high performance, achieving 98% and 99% accuracy on the validation and test EEG datasets, respectively. Our results support the use of TinyML technology in closed-loop neurostimulation devices for epilepsy, as it contributes significantly to the speed and accuracy of seizure detection. Conclusions: The proposed TinyML model demonstrated reliable seizure detection in real-time by analyzing EEG signals and distinguishing epileptic activity from normal brain electrical activity. These findings highlight the potential of TinyML in closed-loop neurostimulation systems for epilepsy, enhancing both speed and accuracy in seizure detection. Full article
(This article belongs to the Special Issue Editor's Choices Series for Methods in Biomedical Informatics Section)
Show Figures

Figure 1

Figure 1
<p>Distribution of values of EEG signals of non-epileptic individuals (<b>left panel</b>) and epileptic patients (<b>right panel</b>). A difference in value range and value distribution is observed.</p>
Full article ">Figure 2
<p>Workflow of the proposed model’s architecture.</p>
Full article ">Figure 3
<p>Scatter plot of labels 0 and 1 predictions in the validation set.</p>
Full article ">Figure 4
<p>Scatter plot of labels 0 and 1 predictions in the test set.</p>
Full article ">Figure 5
<p>ROC curve for the validation set.</p>
Full article ">Figure 6
<p>ROC curve for the test set.</p>
Full article ">
17 pages, 2755 KiB  
Review
Transcatheter Aortic Valve Implantation and Replacement: The Latest Advances and Prospects
by Milos Brankovic and Abhishek Sharma
J. Clin. Med. 2025, 14(6), 1844; https://doi.org/10.3390/jcm14061844 - 9 Mar 2025
Viewed by 159
Abstract
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, particularly in patients at high risk of adverse events for traditional open-heart surgery. Since the early 2000s, TAVR has evolved rapidly with advancements in device technology, procedural techniques, and patient selection [...] Read more.
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, particularly in patients at high risk of adverse events for traditional open-heart surgery. Since the early 2000s, TAVR has evolved rapidly with advancements in device technology, procedural techniques, and patient selection criteria. Over the past 20 years, this catheter-based procedure has significantly improved patient survival and quality of life, demonstrating both the safety and efficacy of TAVR, even in patients at low surgical risk. This paper reviews the latest advances in valve design and strategies for treating aortic stenosis. It explores the challenges with long-term outcomes given the younger age of patients undergoing TAVR and the prospects of emerging technologies to improve long-term outcomes. Full article
Show Figures

Figure 1

Figure 1
<p>Advances and prospects of TAVR treatment. The future of TAVR will focus on providing care based on the patient’s personalized cardiac profile driven by advances in two key areas: valve technology and design (marked in blue to the left) and pre-TAVR planning with post-TAVR care (marked in red to the right). The first area will be centered on (1) post-procedural stroke prevention, (2) minimizing the need for a permanent pacemaker, (3) valve durability, thrombosis, and calcification, (4) paravalvular leak, and (5) designs to fit a broader range of patient anatomies. The second area will involve a comprehensive care model incorporating (1) patient-specific biomarker data, (2) advances in imaging technologies, (3) telemedicine and wearable technology for remote monitoring, (4) AI and machine learning algorithms to improve patient and device selection, and (5) a multidisciplinary heart team.</p>
Full article ">Figure 2
<p>Trend of 1-year cumulative incidences of stroke and disabling stroke across different TAVR trials. The <span class="html-italic">x</span> axis denotes the year when the trial was published, and the <span class="html-italic">y</span> axis denotes the cumulative incidence as a percentage. The dark blue color denotes the treatment arm receiving SAPIEN TAVR valves, and the light blue color denotes the corresponding treatment arm receiving SAVR. The dark red color denotes the treatment arm receiving Evolut TAVR valves, and the light red color denotes the corresponding treatment arm receiving SAVR. The name of the corresponding trial is presented in parentheses. * Reported 2-year cumulative incidence of stroke and disabling stroke. TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.</p>
Full article ">Figure 3
<p>Trend of 30-day and 1-year cumulative incidences of moderate or severe paravalvular leak across different TAVR trials. The <span class="html-italic">x</span> axis denotes the year when the trial was published, and the <span class="html-italic">y</span> axis denotes the cumulative incidence as a percentage. The dark blue color denotes the treatment arm receiving SAPIEN TAVR valves, and the light blue color denotes the corresponding treatment arm receiving SAVR. The dark red color denotes the treatment arm receiving Evolut TAVR valves, and the light red color denotes the corresponding treatment arm receiving SAVR. The name of the corresponding trial is presented in parentheses. TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement; PVL, paravalvular leak.</p>
Full article ">Figure 4
<p>Trend of 30-day cumulative incidence of new permanent pacemaker implantation, major vascular complications, and life-threatening or disabling bleeding across different TAVR trials. The <span class="html-italic">x</span> axis denotes the year when the trial was published, and the <span class="html-italic">y</span> axis denotes the cumulative incidence as a percentage. The dark blue color denotes the treatment arm receiving SAPIEN TAVR valves, and the light blue color denotes the corresponding treatment arm receiving SAVR. The dark red color denotes the treatment arm receiving Evolut TAVR valves, and the light red color denotes the corresponding treatment arm receiving SAVR. The name of the corresponding trial is presented in parentheses. * Reported 1-year cumulative incidence of major vascular complications. TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement; PPM, permanent pacemaker.</p>
Full article ">
12 pages, 3130 KiB  
Article
Fabrication of TiO2 Nanotube Arrays by Progressive Anodization of Ti Thin Film on Insulated Substrates
by Chao-Ching Chiang, Jian-Sian Li, Hsiao-Hsuan Wan, Fan Ren and Josephine F. Esquivel-Upshaw
Materials 2025, 18(6), 1219; https://doi.org/10.3390/ma18061219 - 9 Mar 2025
Viewed by 159
Abstract
Titanium (Ti) thin films deposited on insulated substrates were progressively anodized and formed titanium dioxide (TiO2) nanotube arrays on the surface through a customized anodization tool designed to improve the uniformity and diameters of the nanotubes. With a motorized vertical moving [...] Read more.
Titanium (Ti) thin films deposited on insulated substrates were progressively anodized and formed titanium dioxide (TiO2) nanotube arrays on the surface through a customized anodization tool designed to improve the uniformity and diameters of the nanotubes. With a motorized vertical moving arm attached to the anode, the sample was gradually submerged into the electrolyte at a controlled speed alongside the continuous anodization from the edge to the center to prevent the discontinuation of the conductive Ti layer and its nanotube surface. The effects of Ti deposition rate, anodization voltage, NH4F concentration, and post-etching conditions on nanotube morphology were also explored. Scanning electron microscopy (SEM) analysis revealed that smaller Ti grain sizes, higher anodization voltages, higher electrolyte concentrations, and optimized post-etching times produce uniform, mature nanotubes with larger diameters, which are crucial for practical applications. This work enhances the applicability of nanotube surfaces with non-conductive substrates, such as Zirconia dental implants, and establishes a foundation for future process optimizations. Full article
(This article belongs to the Special Issue Materials for Prosthodontics, Implantology, and Digital Dentistry)
Show Figures

Figure 1

Figure 1
<p>Illustration of the customized anodization tool configuration.</p>
Full article ">Figure 2
<p>Schematic of the anodization process of Ti thin film deposited on a glass substrate.</p>
Full article ">Figure 3
<p>Photographs of Ti thin film on a glass substrate under various anodization conditions. (<b>a</b>) The sample before anodization. (<b>b</b>) Fixed anode where disrupted Ti continuity leads to incomplete nanotube formation. (<b>c</b>) Progressive anodization with excessive anode speed results in shallow nanotubes near the interface. (<b>d</b>) Optimized progressive anodization where the anode speed matches the anodization rate, producing a uniform nanotube array with full anodization.</p>
Full article ">Figure 4
<p>Surface morphology of Ti thin film with the deposition rate of (<b>a</b>) 0.5 Å/s and (<b>b</b>) 3 Å/s and the nanotube formation after anodization process on Ti thin film with the deposition rate of (<b>c</b>) 0.5 Å/s and (<b>d</b>) 3 Å/s.</p>
Full article ">Figure 5
<p>Surface morphology of anodized TiO<sub>2</sub> nanotubes with NH<sub>4</sub>F concentration of 0.5% and voltage of (<b>a</b>) 30 V, (<b>b</b>) 50 V, (<b>c</b>) 70 V, and (<b>d</b>) 90 V.</p>
Full article ">Figure 6
<p>Surface morphology of anodized TiO<sub>2</sub> nanotubes with NH<sub>4</sub>F concentration of (<b>a</b>) 0.5%, (<b>b</b>) 1%, (<b>c</b>) 2%, and (<b>d</b>) 3% and voltage of 90 V.</p>
Full article ">Figure 7
<p>Surface morphology of anodized TiO<sub>2</sub> nanotubes (<b>a</b>) before and (<b>b</b>) after soaking in 3% NH<sub>4</sub>F for 30 min.</p>
Full article ">
Back to TopTop